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3-Nitrotyrosine (NTyr) is considered as a biomarker of the generation of reactive
nitrogen species (RNS). However, it is still difficult to determine its concentration in
biological samples. To develop a reliable and high-throughput method, we optimized
the conditions for high performance liquid chromatography and electrochemical
detection (HPLC–ECD). The best separation of NTyr was achieved using a highly
acidic mobile phase (pH 2.5). The concentration of protein-bound NTyr in plasma
protein was 593.653.8 fmol/mg in rats treated with lipopolysaccharide (LPS) and
114.427.6 fmol/mg in control. After intravenous administration of in vitro-nitrated
plasma protein, NTyr concentration decreased; the half-life was 63.416.8h.
Consistently, protein-bound NTyr concentration in plasma after LPS treatment
declined gradually, but was detectable for 1 week. Our protocol is reproducible and
suitable for analysing multiple clinical samples to study RNS production in vivo.
Key words: electrochemical detection, HPLC, lipopolysaccharide, nitric oxide,
3-nitrotyrosine.
Abbreviations: ECD, electrochemical detection; GS/MS, gas chromatography/mass spectrometry; HPLC,
high performance liquid chromatography; LC/MS, liquid chromatography/mass spectrometry; LPS,
lipopolysaccharide; NO, nitric oxide; NTyr, 3-nitrotyrosine; PBS, phosphate buffered saline; PVDF,
polyvinylidene difluoride; RNS; reactive nitrogen species; TBST, Tris-buffered saline with Tween 20.
Nitric oxide (NO) is a ubiquitous molecule that plays a
central role in homeostatic regulation of the cardiovas-
cular, nervous and immune systems (1). Despite these
important physiological functions, the metabolites of NO
can be toxic. For example, NO reacts with superoxide
anion to form the reactive peroxynitrite anion (ONOO),
which damages DNA, inhibits a variety of enzymes and
initiates lipid peroxidation (2, 3). Excess production of
NO and reactive nitrogen species (RNS) is thought to
promote a number of inflammatory diseases, including
sepsis, ischaemic heart diseases, atherosclerosis and
diabetes mellitus (4–7).
Nitration of protein, caused by RNS such as ONOO–
produces 3-nitrotyrosine (NTyr) in high yield, and a smaller
amount of 3,30-dityrosine, 3,4-dihydroxyphenylalanine
and the corresponding quinine (8, 9). The level of NTyr
is regarded as a biomarker of the generation of RNS
in vivo (10). Protein nitration is associated with more
than 60 human disorders (11). Most studies
have attempted to quantify the concentration of free
NTyr in plasma, or protein-bound NTyr after extensive
hydrolysis of protein samples (12–18). However, the
reported NTyr levels vary considerably, partly because
of the difficulty in quantifying the minute amount of
NTyr in highly complex biological samples. It is also
unknown how long protein-bound NTyr persists in vivo.
Such information is indispensable to evaluate the
biological significance of NTyr.
Various methods have been used to determine NTyr
concentration, including high performance liquid chro-
matography (HPLC) coupled with electrochemical detec-
tor (ECD) (19–24) and mass spectrometry coupled with
liquid or gas chromatography (LC/MS or GS/MS) (12, 18,
25, 26). Although these systems are sensitive enough to
detect NTyr in simple aqueous solution, determining the
concentration of NTyr in biological samples, which
may be as low as 106 to 107 relative to tyrosine
concentration, is cumbersome (19, 25, 27). For example,
mass spectrometric approaches require expensive and
specialized equipment, extensive sample preparation and
isotopically labelled internal standards (15, 28). To
elucidate the pathophysiological significance of RNS
and NTyr formation, it is necessary to establish a
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simple and high-throughput analytical method for accu-
rate quantification of protein-bound NTyr.
To quantify NTyr concentration in biological samples,
we have used an HPLC-dual-mode ECD, comprising two
serial EC cells in the reduction and oxidation/detection
modes (23, 24). This method is highly sensitive and
maintains linearity across a wide range of NTyr
concentrations (21, 23, 24). Moreover, ECD offers an
intrinsic selectivity function, because electrochemically
inert substances are invisible to the ECD. Therefore, the
concentration of the reactive components may be deter-
mined in a complex matrix without the need for
extensive sample purification (29).
In this study, we optimized the protocol for NTyr
quantification using HPLC–ECD, and examined
the persistence of protein-bound NTyr after intra-
venous administration of in vitro-nitrated plasma
proteins or after intraperitoneal administration of
lipopolysaccharide (LPS).
MATERIALS AND METHODS
Animals—Eight-week-old male Sprague-Dawley (SD)
rats were purchased from SLC (Shizuoka, Japan) and
housed in a pathogen-free animal facility under a
standard 12h light/dark cycle. All experiments were
performed under institutional guidelines approved by the
Animal Committee of Kanazawa University.
LPS (Escherichia coli 0111:B4, Sigma, St Louis, MO)
dissolved in phosphate buffered saline (PBS) was
administered intraperitoneally to the rats. At the appro-
priate time points, whole blood was collected from the
inferior vena cava or the tail vein into a heparinized
syringe, while the rat was under anaesthesia. The
plasma was separated by centrifugation. Control
plasma samples were prepared from rats that had been
administered PBS only. The concentration of protein was
determined using the BCA protein quantification kit
(Pierce, Wobum, MA).
In vitro Nitration of Rat Plasma Protein—Rat plasma
was dialysed against four exchanges of 100 volumes of
PBS at 48C. The sample was cleared by centrifugation at
2,500 g for 20min. Plasma proteins were nitrated
in vitro by adding 5mM sodium nitrite and adjusting
the pH to 3.0 with HCl. After 30-min incubation at room
temperature, the reaction mixture was neutralized with
1M Tris–HCl (pH 8.0) and dialysed against four
exchanges of 100 volumes of PBS at 48C. The nitration
of plasma protein was verified by western analysis using
an anti-nitrotyrosine antibody, as described later.
The nitrated plasma proteins were infused into
rats through the tail vein, to achieve a concentration
of 500 pmol NTyr/mg plasma protein 1h after the infusion.
Plasma samples (70 ml) were obtained before; 1, 3, 8 and
24h after; and 3, 4, 5 and 7d after the infusion.
Sample Preparation—Rat plasma (95–110 ml, equiva-
lent to 5mg plasma protein) was diluted to 500 ml with
0.1M acetate buffer (pH 7.4), precipitated by adding
800ml of ice-cold acetonitrile and centrifuged at 2800 g
for 10min. The pellet was washed with acetonitrile/0.1M
acetate buffer (8:5 v/v) to remove nitrite and nitrate
present in plasma, and resuspended in 0.1M acetate
buffer (pH 7.4) by two 10-s cycles of sonication. The
resuspended protein precipitate was digested with 1mg
pronase (Roche, Basel, Switzerland), which was
dialysed against nitrite- and nitrate-free 0.1M acetate
buffer (pH 7.4), for 14h at 508C with continuous rotation.
The digested product was centrifuged, and the super-
natant was ultrafiltrated using Ultra free MC (molecular
cutoff 10,000, Millipore, Billerica, MA).
Validity of sample preparation was assessed by
measuring the concentration of free tyrosine in the
filtrated sample, using an HPLC-ultraviolet detection
method. Tyrosine (Sigma, St Louis, MO) was dissolved
in 0.1M acetate buffer (pH 7.4) at the concentration
0.1–10mM as the standard. A coefficient of variation
of the concentration of tyrosine in the sample was55%.
HPLC–ECD—Fifty microlitres of the filtrated sample
was fractionated with an SC-50ODS column
(3mm 150mm, 5mm, Eicom, Kyoto, Japan) and 200mM
phosphate buffer containing 5 mg/ml EDTA and 2% acet-
onitrile, using the HPLC–ECD system (PEC-510/HTEC-
500, Eicom). The flow rate was 500 ml/min. The pH, ionic
strength and the concentration of organic solvent in the
mobile phase were varied, and their effects on the retention
time and resolution of a NTyr peak were examined.
3-Nitrotyrosine (Sigma) dissolved in 0.1M acetate buffer
was used as the standard.
The sensitivity and linearity of the HPLC–ECD system
to NTyr were verified by analysing serial dilutions of the
NTyr standard, which ranged from 10pM to 1 mM. Applied
potentials for the dual-mode ECDwere adjusted to achieve
the highest signal-to-noise ratio between NTyr and other
components in the digested plasma proteins. The applied
potentials were from 900 to 500mV for the reduction
cell and from 50 to 300mV for the oxidation/detection cell.
The concentration of NTyr was determined by using the
NTyr standard (Sigma) dissolved in 0.1M acetate buffer
(pH 7.4). The amount of NTyr was expressed as micromol/
mg plasma protein as determined using the BCA protein
quantification kit.
Western Analysis—Protein samples (5 mg) were fractio-
nated on two 10% polyacrylamide gels in parallel. One gel
was stained with Coomassie brilliant blue (CBB) to confirm
the protein loading, and the other gel was blotted onto a
PVDF membrane. The membrane was blocked with 5%
skim milk in Tris-buffered saline with 0.5% Tween 20
(TBST), and incubated with a monoclonal anti-nitrotyr-
osine antibody diluted 1:2000 (Upstate, Charlottesville,
VA) (30). After an extensive wash with TBST, the
membrane was incubated with anti-mouse antibody con-
jugated with horseradish peroxidase (Amersham,
Piscataway, NJ). Nitrated protein was detected using a
Southern lightning system (PerkinElmer, Wellesley, MA).
Statistics—Student’s t-test was used for statistical
analysis using Statview for Windows version 5.0
(SAS Institute, Cary, NJ). P50.05 was regarded as
significant.
RESULTS
Conventional method of NTyr analysis by HPLC–ECD
have used phosphate or sodium acetate buffer at pH 4.3
to 7.5 and an organic solvent at a concentration of
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several percent for the mobile phase (19, 21–23). We used
200mM phosphate buffer (pH 4.3) and 2% acetonitrile.
Our method has high sensitivity and linearity across the
standard NTyr range of 50 fmol to 1 mmol (23, 24, 31).
However, we also observed insurmountable interference
with the peak of NTyr caused by various plasma
components (Fig. 1). This affected the reproducibility
and reliability of NTyr measurement (see Fig. 4).
Improved NTyr Separation—To optimize the separa-
tion of NTyr from other plasma components, we
examined the effect of a mobile phase on NTyr separa-
tion. The retention time of NTyr was highly dependent
on the pH of the mobile phase (Fig. 2A) and the
concentration of acetonitrile (Fig. 2B), whereas the
ionic strength had a minor effect (Fig. 2A). The retention
time was prolonged by a strongly acidic mobile phase:
17min at pH 4.3, 20min at pH 3.0 and 27min at pH 2.5.
Because prolongation of the retention time might
improve the separation of the NTyr peak from other
components in plasma, we tested the effects of pH and
the concentration of acetonitrile in the mobile phase on
the resolution of the NTyr peak in plasma samples from
LPS-treated and control rats. As anticipated, decreasing
the pH of the mobile phase improved the resolution of
the NTyr peak in the LPS-treated rat plasma. The best
separation was achieved with a mobile phase at pH 2.5
and with 2.0% acetonitrile (Fig. 3A). Under this condi-
tion, the peak area of NTyr present in the control rat
plasma was close to the lower detection limit, and less
than one-tenth of that at pH 4.3 (e.g. Fig. 3A compare
with Fig. 1). To eliminate a possibility to produce
artificial NTyr with acidic mobile phase, 1mM tyrosine
standard spiked with or without 10nM NTyr was
analysed with HPLC with acidic mobile phase (ranging
from pH 2.1 to 4.5). No artificial NTyr production was
observed, probably because we removed nitrite/nitrate
from plasma protein, and the separation of tyrosine with
nitrite, if present, might start soon after sample injection
within the separation column.
Optimizing Applied Potentials—To increase the speci-
ficity for NTyr detection further, we optimized the
applied potentials in the reduction and oxidation/detec-
tion cells of the dual-mode ECD. Our former protocol at
pH 4.3 used 900 and 300mV for the reduction and
oxidation/detection cells, respectively. Decreasing the
applied potential in the reduction cell from 900 to
600mV markedly decreased the background current
and peak areas of various components in plasma,
whereas the peak area of NTyr was well preserved
(data not shown).
Further improvement of the signal-to-noise ratio was
achieved by decreasing the oxidation/detection potential.
The peak of NTyr was maintained by decreasing the
oxidation/detection potential from 200 to 75mV (Fig. 3B).
In contrast, most peaks of the other components
decreased markedly and some disappeared completely
from the chromatogram (Fig. 3C). Accordingly, the
optimal applied potentials for NTyr analysis at pH 2.5
were 600mV for the reduction cell and 75mV for the
oxidation/detection cells.
Fig. 1. Analysis of NTyr in rat plasma samples at pH 4.3.
Rats were treated with or without LPS (5mg/kg), and plasma
samples were prepared 24h later. Following pronase digestion
and ultrafiltration of plasma protein, the sample was analysed
with HPLC–ECD, using a mobile phase at pH 4.3. The
potentials applied to the reduction and oxidation/detection
cells were 900 and 300mV, respectively. The resolution
of the NTyr peak was affected by adjacent peaks at pH 4.3.
(a) LPS-treated rat plasma sample; (b) control rat plasma and
(c) 5 nM NTyr standard.
Fig. 2. The effect of HPLC conditions on the retention
time of NTyr. (A) Relationship between pH, ionic strength of
the mobile phase and the retention time of NTyr. The NTyr
standard sample was analysed with HPLC–ECD using various
mobile phases. (B) The effect of acetonitrile concentration in the
mobile phase on the retention time of NTyr. The concentration
of acetonitrile was varied from 2 to 10% in a highly acidic mobile
phase (200mM phosphate buffer at pH 2.5 and 5 mg/ml EDTA).
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Reproducibility of NTyr Measurement—To assess the
reproducibility of the new protocol at pH 2.5, we
prepared a batch of sample from pooled rat plasma and
analysed it repeatedly using both protocols at pH 2.5
and pH 4.3. The reproducibility of NTyr measurement
was apparently improved at pH 2.5 (Fig. 4). Moreover,
the shape and resolution of NTyr peak were uniform
and reproducible at pH 2.5 (Fig. 3A and B). The
concentration of NTyr measured at pH 2.5 was
593.6 53.8 fmol/mg plasma protein from LPS-treated
rats and 114.4 27.6 fmol/mg in control rats (P50.001).
The respective values at pH 4.3 were 1434.0 456.0
and 865.2 290.8 fmol/mg in plasma protein from
LPS-treated and control rats.
Disposition of Nitrated Plasma Protein in the Rat
Circulation—To examine the reliability of the protocol for
measuring NTyr concentration, we prepared nitrated rat
plasma protein in vitro and infused it into four rats to
achieve 103 times the amount of protein-bound NTyr
found in normal rat plasma immediately after the
infusion. The amount of NTyr declined rapidly in the
rat plasma during the first 24h. This rapid-elimination
phase was followed by a more prolonged elimina-
tion phase (Fig. 5A and B). The average half-life of the
latter phase for protein-bound NTyr was 63.4 16.8 h
(n¼ 4). In addition, the high concentration of nitrated
protein in rat plasma allowed us to detect protein-bound
NTyr by western analysis, using an anti-NTyr antibody.
As shown in Fig. 5B, the amount of all nitrated plasma
proteins decreased and that of nitrated albumin detected
by western blot analysis correlated with the peak area of
NTyr on the HPLC–ECD chromatograms.
Protein-bound NTyr in Rat Plasma after LPS
Administration—Finally, we examined the amount of
protein-bound NTyr in rat plasma after administration of
0.5, 5 and 10mg/kg LPS. A series of typical chromato-
grams is shown in Fig. 6A. The amount of NTyr reached
a maximum 24h after administration of 5mg/kg LPS.
It was 10 times higher than that in control rat plasma
(Fig. 6A and B). Thereafter, the amount of NTyr
gradually decreased over 1 week (Fig. 6B). The highest
dose of LPS (10mg/kg) elevated NTyr concentration
further to a level more than 1.5 times higher than that
produced by 5mg/kg LPS at 12h (Fig. 6B). The lowest
dose of LPS (0.5mg/kg) produced a 2-fold increase in
NTyr concentration at 12h, compared with control rat
plasma, after which it decreased to normal levels within
36h after the LPS administration (Fig. 6B).
Fig. 3. NTyr analysis of rat plasma samples at pH 2.5. (A)
Plasma samples from LPS-treated or control rats were analysed
with HPLC–ECD using a highly acidic mobile phase at pH 2.5.
(a) LPS-treated rat plasma; (b) control rat plasma and (c) 5 nM
NTyr standard. (B) The profile of electrochemical responses for
NTyr. NTyr standard (250 fmol) was analysed repeatedly (n¼3)
with a mobile phase at pH 2.5, varying the potential applied
applied to the oxidation/detection cell. The applied potential to
the reduction cell was at 600mV. (C) Improved specificity to
NTyr by decreasing the applied potential to the oxidation/
detection cell. The applied potential to the reduction cell was
fixed at 600mV, and that to the oxidation/detection cell was
varied at (a) 200mV, (b) 150mV, (c) 100mV and (d) 75mV. The
peak area of NTyr was well preserved, whereas other peaks
decreased as the applied potential decreased.
Fig. 4. Reproducibility of NTyr measurement at pH 2.5
and pH 4.3. The same samples, prepared from pooled rat
plasma from LPS-treated or control rats, were analysed
repeatedly (15 times) at both pH 2.5 and pH 4.3. The
reproducibility of NTyr measurement was better using the
new protocol at pH 2.5 than when using the former protocol at
pH 4.3. Coefficient of variation was 9.1 (pH 2.5) vs 31.8 (pH 4.3)
for LPS-treated rats and 24.1 (pH 2.5) vs 33.6 (pH 4.3) for
control rats.
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DISCUSSION
An accurate and reproducible method to measure
NTyr is crucial to our understanding of the role of
nitration reactions in pathophysiological processes. Such
a method should also be applicable to biological samples,
which contain various interfering substances. Our early
attempts to determine the concentration of NTyr required
repeated measurements for each sample, because of
variable amounts of NTyr due to poor separation of
NTyr from other components in plasma at pH 4.3.
To optimize the protocol, we tested more than 20
conditions for HPLC, and found that a single peak in the
LPS-treated rat plasma always had the same retention
time as for the NTyr standard (ranging from 8 to 33min).
We also found that the ratio of the peak in LPS-treated
rat plasma and that of NTyr standard became constant,
when the pH of the mobile phase was decreased to53.0.
We believe that this indicates successful separation of
NTyr from other components in plasma, which have
similar retention times as NTyr under the conventional
assay conditions. Further evidence was provided during
the optimization of the potentials applied to ECD, which
showed that these peaks share the same electrochemical
Fig. 5. Elimination of nitrated plasma protein from the
rat circulation. (A) Semilogarithmic plot of the concentration
of NTyr (fmol/mg plasma protein) vs time after an i.v. bolus
infusion of nitrated plasma protein. The values shown are the
mean  standard deviation (n¼ 4). (B) Representative chroma-
tograms are from one rat after administration of nitrated
plasma protein. The same samples were subjected to western
analysis for nitrated albumin with an anti-NTyr antibody. As
control, the same samples were electrophoresed in parallel,
stained with coomassie brilliant blue (CBB), and shown in their
albumin bands.
Fig. 6. The time course of protein-bound NTyr in rat
plasma after LPS administration. (A) Chromatograms of
HPLC–ECD to measure NTyr concentration at pH 2.5. Rat blood
samples were collected from the tail vein before, 4, 8, 12, 24, 36,
48 and 72h: and 7 days after LPS administration (5mg/kg).
Discrete peaks of NTyr were detected at the same retention time
for the NTyr standard (Std). (B) Time course of protein-bound
NTyr in rat plasma. Four groups of animals (n¼ 3 each) were
administered 0 (*), 0.5 (i), 5 (œ), or 10 (s)mg/kg LPS, and
blood samples were collected at each time point. The concentra-
tion of NTyr determined with HPLC–ECD. The values shown
are the mean standard deviation. At the highest dose of LPS
(10mg/kg), two of the three animals died within 24h.
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properties because the peak ratio remained constant over
a wide range of applied potentials. Therefore, we
conclude that the combination of the mobile phase at
pH 2.5 and decreased applied potentials to ECD achieves
successful separation of NTyr in digested rat plasma
protein. Interestingly, the differences in the concentra-
tion of NTyr in rat plasma with or without LPS
treatment were comparable at pH 2.5 (239.6 fmol/mg)
and at pH 4.3 (284.4 fmol/mg) (see Fig. 4). We speculated
that this indicates proper separation of the NTyr peak
from other components in plasma samples.
The use of a highly acidic mobile phase is a
prerequisite for accurately quantifying NTyr concentra-
tion using HPLC–ECD. However, under the strongly
acidic condition, tyrosine is nitrated by nitrite often
present in biological samples (32, 33). For example,
normal human serum contains 20 mM nitrite. To deny the
possible formation of NTyr as an artefact, we added
sodium nitrite (50mM) to digested control rat plasma
protein and injected the mixture into the HPLC–ECD
system with a mobile phase at pH 2.5. The digestion
product of rat plasma protein contains 3mM free
tyrosine. We detected no artefactual NTyr even after
incubating the mixture for 1h at room temperature.
Because that the plasma protein had been precipitated
and washed twice with nitrite-free acetonitrile/acetate
buffer, the sample was kept at pH 7.4 throughout sample
preparation, and the separation of tyrosine and nitrite
immediately started in the separation column, artefac-
tual NTyr formation within the HPLC line with acidic
mobile phase was below detectable level in our protocol.
The amount of protein-bound NTyr was significantly
lower and the measurement more reproducible at pH 2.5
than at pH 4.3. It was 100–1000 fmol/mg in rat plasma
protein at pH 2.5. Since the concentration of tyrosine in
the same samples was about 0.3 mmol/mg plasma protein,
the molar ratio of NTyr to tyrosine was 2.0 0.19 mmol of
NTyr/mol of tyrosine in plasma protein from rats treated
with 5mg/kg of LPS and 0.37 0.15mmol of NTyr/mol of
tyrosine in untreated rats. Although we should consider
the tyrosine released from pronase itself (1mg of pronase
to 5mg of plasma protein), our results are the lowest
values ever reported using HPLC–ECD to measure
NTyr, except for the estimation by Shigenaga et al.
(19). They used a sophisticated method to convert NTyr
to N-acetyl-3-aminotyrosine before injecting the sample
into HPLC–ECD. Their estimation is comparable to our
results. In addition, our results are also similar to 4–18
and 1.55 mmol of NTyr/mol of tyrosine measured by LC-
tandem MS (25) and GC-tandem MS (34), respectively.
Cumulatively, our data suggest that the amount of
protein-bound NTyr in normal rat plasma may be less
than 1mmol of NTyr/mol of tyrosine. However, definitive
identification of a compound(s) in the peak of our interest
by other methods e.g., mass spectrometry coupled with
the LC or GC, is warranted.
The in vivo half-life of free NTyr is 68.5 18.4min,
after a single bolus dose of free NTyr (35). However, little
information is available on the half-life of protein-bound
NTyr. We analysed the elimination of in vitro-nitrated
plasma protein from the rat circulation, and measured
the in vivo half-life of nitrated plasma protein as
63.4 16.8 h during the prolonged elimination phase.
The western analysis of nitrated albumin showed similar
elimination kinetics. The half-life of normal albumin is
18 to 21 days, and the nitrated albumin had a much
shorter half-life than its normal counterpart did. The
reason for the faster elimination of nitrated albumin
is unknown. Because the protein was nitrated at pH 3.0
in vitro, it is possible that nitrated plasma proteins are
recognized and eliminated by a similar mechanism to
that, which scavenges denatured plasma protein (36). It
is likely that the actual half-life of in vivo-nitrated
plasma protein is no shorter than the value we observed.
These results provide solid evidence that protein-bound
NTyr persists long enough to be a biomarker for in vivo
RNS production. We found consistently that protein-
bound NTyr persists in rat plasma for a week after
administration of 5mg/kg LPS. Although the NTyr
concentration in plasma depends on the balance between
its production and elimination, the gradual decline of
NTyr concentration, starting from 24h after LPS
administration, may indicate a constant rate of elimina-
tion of in vivo-nitrated protein from the circulation. To
determine the fate of protein-bound NTyr in vivo, it is
necessary to identify which protein species are nitrated
after LPS administration.
In rat plasma protein, the abundance of protein-bound
NTyr was 510 NTyr residues per 1 106 tyrosine
residue. Despite of its rarity, recent studies demonstrate
the biological importance of tyrosine nitration, which is a
highly site-specific reaction. MacMillan-Crow et al. (37)
demonstrates that nitration of manganese superoxide
dismutase (Mn-SOD) completely inhibits its enzymatic
activity. Clinically, the inhibition of Mn-SOD activity
by iNOS-dependent nitration was reported in acutely
rejecting cardiac transplants (38). The site-specific
protein nitration also affects the function of apolipopro-
tein A-1 (39, 40), angiotensin II (41), a-synuclein in
Parkinson’s disease (42), a-enolase in a transgenic mouse
model of familial amyotrophic lateral sclerosis (43).
Slight alteration of the protein-bound NTyr level in
plasma protein might reflect an important aspect of the
RNS generation and metabolism.
In conclusion, we have developed a new protocol to
quantify protein-bound NTyr, and have demonstrated
the time course of NTyr disappearance from plasma after
administration of in vitro-nitrated protein or LPS.
Because our new protocol does not require elaborate
sample purification or derivatization procedures, it is
suitable for quantification of NTyr in multiple samples,
and might contribute to our understanding of the
importance of RNS generation in disease processes.
This study was supported by the Japanese Ministry of
Education, Culture, Sports, Science and Technology, and the
Promotion and Mutual Aid Corporation for Private Schools
of Japan.
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